AU2017258242B2 - Treatment of liver, biliary tract and pancreatic disorders - Google Patents

Treatment of liver, biliary tract and pancreatic disorders Download PDF

Info

Publication number
AU2017258242B2
AU2017258242B2 AU2017258242A AU2017258242A AU2017258242B2 AU 2017258242 B2 AU2017258242 B2 AU 2017258242B2 AU 2017258242 A AU2017258242 A AU 2017258242A AU 2017258242 A AU2017258242 A AU 2017258242A AU 2017258242 B2 AU2017258242 B2 AU 2017258242B2
Authority
AU
Australia
Prior art keywords
defensin
fat
hbd
high fat
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017258242A
Other languages
English (en)
Other versions
AU2017258242A1 (en
Inventor
Søren Kjærulff
Peter NORDKILD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Publication of AU2017258242A1 publication Critical patent/AU2017258242A1/en
Assigned to NOVOZYMES A/S reassignment NOVOZYMES A/S Request for Assignment Assignors: DEFENSIN THERAPEUTICS APS
Application granted granted Critical
Publication of AU2017258242B2 publication Critical patent/AU2017258242B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017258242A 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders Expired - Fee Related AU2017258242B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (2)

Publication Number Publication Date
AU2017258242A1 AU2017258242A1 (en) 2018-11-29
AU2017258242B2 true AU2017258242B2 (en) 2024-04-04

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017258242A Expired - Fee Related AU2017258242B2 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Country Status (11)

Country Link
US (1) US12076368B2 (cg-RX-API-DMAC7.html)
EP (1) EP3448409B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019514908A (cg-RX-API-DMAC7.html)
KR (1) KR102465341B1 (cg-RX-API-DMAC7.html)
CN (1) CN109414474B (cg-RX-API-DMAC7.html)
AU (1) AU2017258242B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018071972A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022497A1 (cg-RX-API-DMAC7.html)
RU (1) RU2740913C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201809086YA (cg-RX-API-DMAC7.html)
WO (1) WO2017186250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US20140073563A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU2003231947A1 (en) 2002-05-31 2003-12-19 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20100104529A1 (en) 2006-05-01 2010-04-29 England Robert L TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
HUE044174T2 (hu) 2008-02-01 2019-10-28 Ascendis Pharma As Önhasítható linkert tartalmazó elõvegyület
JP2011528332A (ja) 2008-07-18 2011-11-17 ノボザイムス アデニウム バイオテック アクティーゼルスカブ 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
CA2750727A1 (en) 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
US9217021B2 (en) * 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
AU2017212534A1 (en) 2016-01-26 2018-07-26 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
WO2017185549A1 (zh) * 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
US20140073563A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
CN104971343A (zh) * 2015-07-13 2015-10-14 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063A (zh) * 2015-10-19 2016-04-20 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mattar, E. et al., 'Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4', Molecular BioSystems, (2016-01-01), vol. 12, no. 9, pages 2785 - 2797, doi: 10.1039/C6MB00283H. *

Also Published As

Publication number Publication date
CN109414474B (zh) 2024-07-02
CA3022497A1 (en) 2017-11-02
RU2740913C2 (ru) 2021-01-21
EP3448409A1 (en) 2019-03-06
EP3448409B1 (en) 2025-12-03
CN109414474A (zh) 2019-03-01
RU2018141326A3 (cg-RX-API-DMAC7.html) 2020-08-06
RU2018141326A (ru) 2020-05-29
SG11201809086YA (en) 2018-11-29
AU2017258242A1 (en) 2018-11-29
US20190192626A1 (en) 2019-06-27
WO2017186250A1 (en) 2017-11-02
KR20190003592A (ko) 2019-01-09
KR102465341B1 (ko) 2022-11-09
JP2019514908A (ja) 2019-06-06
BR112018071972A2 (pt) 2019-02-26
US12076368B2 (en) 2024-09-03

Similar Documents

Publication Publication Date Title
EP3407905B1 (en) Methods for modulating intestinal microbiota
AU2017258242B2 (en) Treatment of liver, biliary tract and pancreatic disorders
TWI700291B (zh) 升糖素及glp-1共激動劑化合物
ES2802099T3 (es) Una composición para el tratamiento de la diabetes que comprende un análogo de oxintomodulina
JP2023071869A (ja) グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US20130336893A1 (en) Exedin-4 Peptide Analogues
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
US20050245441A1 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
TW201202265A (en) Glucagon analogues
KR20230023059A (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
US20220088148A1 (en) A pharmaceutical composition comprising insulin and trigonal glucagon/glp-1/gip receptor agonist
KR20240021212A (ko) 비만 및 비만-관련 장애의 치료
CN116970062B (zh) 一种超长效glp-1多肽衍生物及其制备方法和用途
CN102781476A (zh) 改进经口递送的方法
CN105658234A (zh) 拟胰岛淀粉样多肽化合物与聚乙二醇的非-凝聚生物缀合物
HK40001163B (en) Methods for modulating intestinal microbiota
WO2023120363A1 (ja) 血糖値上昇抑制用組成物
CN114867742A (zh) 胰高血糖素和glp-1受体的钉合内酰胺共激动剂

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVOZYMES A/S

Free format text: FORMER APPLICANT(S): DEFENSIN THERAPEUTICS APS

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee